Shortly after announcing its fourth collaboration with
), biotech company
) announced another deal - this time with biopharma company,
Biogen and Amicus will collaborate for the identification,
development and commercialization of Parkinson's disease
The collaboration is based on preclinical studies performed by
Amicus as well as independent published research which indicate
that increasing activity of the lysosomal enzyme
glucocerobrosidase (GCase) in the brain may correct
alpha-synuclein pathology and other deficits associated with
Amicus' expertise in the discovery of novel small molecules
that increase GCase activity in the brain will be put to use
under this multi-year collaboration for the identification of
potential treatments for Parkinson's.
Biogen, in turn, has agreed to finance all discovery,
development, and commercialization activities. Biogen will also
reimburse Amicus for all full-time employees involved in the
project. Moreover, Biogen will make development and regulatory
based milestone payments and royalties on worldwide sales.
The deal is in-line with Biogen's efforts to expand its
neurodegenerative diseases pipeline. Meanwhile, Amicus is gaining
a strong development partner in the form of Biogen.
While Amicus is a Zacks Rank #3 (Hold) stock, Biogen currently
carries a Zacks Rank #1 (Strong Buy). Key products, Avonex and
Tysabri, should continue contributing significantly to sales.
Tecfidera should help drive long-term growth. Biogen has several
development and regulatory catalysts coming up in the next few
quarters. With Tecfidera launched, we expect investor focus to
remain on its commercialization and sales ramp up.
Other stocks that currently look well-positioned and which
carry a Zacks Rank #1 include
Gilead Sciences Inc.
BIOGEN IDEC INC (BIIB): Free Stock Analysis
AMICUS THERAPT (FOLD): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
ISIS PHARMACEUT (ISIS): Free Stock Analysis
To read this article on Zacks.com click here.